-
1
-
-
35648995976
-
Interleukin-6 and its receptors in cancer. Implication for translational therapeutics
-
Review
-
DS Hong LS Angelo R Kurzrock 2007 Interleukin-6 and its receptors in cancer. Implication for translational therapeutics Cancer. 110 1911 28 Review
-
(2007)
Cancer.
, vol.110
, pp. 1911-28
-
-
Hong, D.S.1
Angelo, L.S.2
Kurzrock, R.3
-
2
-
-
26944456960
-
Interleukin-6: An osteotropic factor influencing bone formation?
-
N Franchimont S Wertz M Malaise 2005 Interleukin-6: an osteotropic factor influencing bone formation? Bone. 37 601 6
-
(2005)
Bone.
, vol.37
, pp. 601-6
-
-
Franchimont, N.1
Wertz, S.2
Malaise, M.3
-
3
-
-
1642432081
-
IL-6, RANKL, TNFalpha/IL-1: Interrelations in bone resorption pathophysiology
-
S Kwan Tat M Padrines S Théoleyre D Heymann F Yannick 2004 IL-6, RANKL, TNFalpha/IL-1: interrelations in bone resorption pathophysiology Cytokine Growth Factor Rev. 15 1 49 60
-
(2004)
Cytokine Growth Factor Rev.
, vol.15
, Issue.1
, pp. 49-60
-
-
Kwan Tat, S.1
Padrines, M.2
Théoleyre, S.3
Heymann, D.4
Yannick, F.5
-
4
-
-
33947414063
-
Significance of interleukin-6 in breast cancer
-
Review
-
H Knüpfer R Preiss 2007 Significance of interleukin-6 in breast cancer Breast Cancer Res Treat. 102 129 35 Review
-
(2007)
Breast Cancer Res Treat.
, vol.102
, pp. 129-35
-
-
Knüpfer, H.1
Preiss, R.2
-
7
-
-
0035667565
-
Plasma levels of interleukin-6 and its soluble receptors are associated with prostate cancer progression and metastasis
-
SF Shariat B Andrews MW Kattan J Kim TM Wheeler KM Slawin 2001 Plasma levels of interleukin-6 and its soluble receptors are associated with prostate cancer progression and metastasis Urology. 58 1008 15
-
(2001)
Urology.
, vol.58
, pp. 1008-15
-
-
Shariat, S.F.1
Andrews, B.2
Kattan, M.W.3
Kim, J.4
Wheeler, T.M.5
Slawin, K.M.6
-
9
-
-
38849159247
-
Biochemical properties and regulation of cathepsin K activity
-
Lecaille F, Brömme D, Lalmanach G. Biochemical properties and regulation of cathepsin K activity. Biochimie. 2007;90(2):208-26.
-
(2007)
Biochimie
, vol.90
, Issue.2
, pp. 208-26
-
-
Lecaille, F.1
Brömme, D.2
Lalmanach, G.3
-
11
-
-
0141702182
-
The use of zoledronic acid in the management of metastatic bone disease and hypercalcaemia
-
H Neville-Webbe RE Coleman 2003 The use of zoledronic acid in the management of metastatic bone disease and hypercalcaemia Palliat Med. 17 6 539 53
-
(2003)
Palliat Med.
, vol.17
, Issue.6
, pp. 539-53
-
-
Neville-Webbe, H.1
Coleman, R.E.2
-
12
-
-
28144437623
-
The use of zoledronic acid in patients with bone metastases from prostate carcinoma: Effects on analgesic response and bone metabolism markers
-
F Fulfaro G Leto G Badalamenti C Arcara G Cicero MR Valerio 2005 The use of zoledronic acid in patients with bone metastases from prostate carcinoma: effects on analgesic response and bone metabolism markers J Chemother. 17 5 555 9
-
(2005)
J Chemother.
, vol.17
, Issue.5
, pp. 555-9
-
-
Fulfaro, F.1
Leto, G.2
Badalamenti, G.3
Arcara, C.4
Cicero, G.5
Valerio, M.R.6
-
14
-
-
0035049888
-
Ethical principles for medical research involving human subjects
-
World Medical Association Declaration of Helsinki
-
World Medical Association Declaration of Helsinki 2001 Ethical principles for medical research involving human subjects Bull World Health Organ. 79 4 373 4
-
(2001)
Bull World Health Organ.
, vol.79
, Issue.4
, pp. 373-4
-
-
-
15
-
-
18644373689
-
Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases
-
T Chen J Berenson R Vescio R Swift A Gilchick S Goodin 2002 Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases J Clin Pharmacol. 42 11 1228 36
-
(2002)
J Clin Pharmacol.
, vol.42
, Issue.11
, pp. 1228-36
-
-
Chen, T.1
Berenson, J.2
Vescio, R.3
Swift, R.4
Gilchick, A.5
Goodin, S.6
-
16
-
-
0020083498
-
The meaning and use of the area under a receiver operating characteristic (ROC) curve
-
JA Hanely BJ McNeil 1982 The meaning and use of the area under a receiver operating characteristic (ROC) curve Radiology. 143 29 36
-
(1982)
Radiology.
, vol.143
, pp. 29-36
-
-
Hanely, J.A.1
McNeil, B.J.2
-
17
-
-
0020524559
-
A method of comparing the areas under receiver operating characteristic curves derived from the same cases
-
JA Hanley BJ McNeil 1983 A method of comparing the areas under receiver operating characteristic curves derived from the same cases Radiology. 148 839 43
-
(1983)
Radiology.
, vol.148
, pp. 839-43
-
-
Hanley, J.A.1
McNeil, B.J.2
-
18
-
-
33847196730
-
Diagnostic accuracy of cystatin C compared to serum creatinine for the estimation of renal dysfunction in adults and children-a meta-analysis
-
Review
-
JF Roos J Doust SE Tett CM Kirkpatrick 2007 Diagnostic accuracy of cystatin C compared to serum creatinine for the estimation of renal dysfunction in adults and children-a meta-analysis Clin Biochem. 40 5-6 383 91 Review
-
(2007)
Clin Biochem.
, vol.40
, Issue.56
, pp. 383-91
-
-
Roos, J.F.1
Doust, J.2
Tett, S.E.3
Kirkpatrick, C.M.4
-
19
-
-
0346656567
-
Immunohistochemical analysis of the IL-6 family of cytokines and their receptors in benign, hyperplasic, and malignant human prostate
-
M Royuela M Ricote MS Parsons I García-Tuñón R Paniagua MP de Miguel 2004 Immunohistochemical analysis of the IL-6 family of cytokines and their receptors in benign, hyperplasic, and malignant human prostate J Pathol. 202 41 9
-
(2004)
J Pathol.
, vol.202
, pp. 41-9
-
-
Royuela, M.1
Ricote, M.2
Parsons, M.S.3
García-Tuñón, I.4
Paniagua, R.5
De Miguel, M.P.6
-
20
-
-
3042823539
-
Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer
-
V Michalaki K Syrigos P Charles J Waxman 2004 Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer Br J Cancer. 90 12 2312 6
-
(2004)
Br J Cancer.
, vol.90
, Issue.12
, pp. 2312-6
-
-
Michalaki, V.1
Syrigos, K.2
Charles, P.3
Waxman, J.4
-
21
-
-
33745100294
-
Aberrant expression of Cystatin C in prostate cancer is associated with neuroendocrine differentiation
-
T Jiborn M Abrahamson V Gadaleanu A Lundwall A Bjartell 2006 Aberrant expression of Cystatin C in prostate cancer is associated with neuroendocrine differentiation Br J Urol Int. 98 189 96
-
(2006)
Br J Urol Int.
, vol.98
, pp. 189-96
-
-
Jiborn, T.1
Abrahamson, M.2
Gadaleanu, V.3
Lundwall, A.4
Bjartell, A.5
-
22
-
-
33646067439
-
Towards novel anticancer strategies based on cystatin function
-
Review
-
D Keppler 2006 Towards novel anticancer strategies based on cystatin function Cancer Lett. 235 159 76 Review
-
(2006)
Cancer Lett.
, vol.235
, pp. 159-76
-
-
Keppler, D.1
-
24
-
-
0034128337
-
Cysteine proteinases and their inhibitors in extracellular fluids: Markers for diagnosis and prognosis in cancer
-
J Kos T Werle T Lah N Brünner 2000 Cysteine proteinases and their inhibitors in extracellular fluids: markers for diagnosis and prognosis in cancer Int J Biol Markers. 15 84 9
-
(2000)
Int J Biol Markers.
, vol.15
, pp. 84-9
-
-
Kos, J.1
Werle, T.2
Lah, T.3
Brünner, N.4
-
26
-
-
33947247395
-
Is benign prostatic hyperplasia (BPH) an immune inflammatory disease?
-
G Kramer D Mitteregger M Marberger 2007 Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur Urol. 51 5 1202 16
-
(2007)
Eur Urol.
, vol.51
, Issue.5
, pp. 1202-16
-
-
Kramer, G.1
Mitteregger, D.2
Marberger, M.3
-
27
-
-
0030920461
-
Cystatin C, an inhibitor of bone resorption produced by osteoblasts
-
UH Lerner L Johansson M Ranjsö JB Rosenquist FP Reinholt A Grubb 1997 Cystatin C, an inhibitor of bone resorption produced by osteoblasts Acta Physiol Scand. 161 1 81 92
-
(1997)
Acta Physiol Scand.
, vol.161
, Issue.1
, pp. 81-92
-
-
Lerner, U.H.1
Johansson, L.2
Ranjsö, M.3
Rosenquist, J.B.4
Reinholt, F.P.5
Grubb, A.6
-
30
-
-
23944446040
-
Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients
-
G Ferretti A Fabi P Carlini P Papaldo P Cordiali Fei 2005 Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients Oncology. 69 1 35 43
-
(2005)
Oncology.
, vol.69
, Issue.1
, pp. 35-43
-
-
Ferretti, G.1
Fabi, A.2
Carlini, P.3
Papaldo, P.4
Cordiali Fei, P.5
-
31
-
-
0033153362
-
Osteomimetic properties of prostate cancer cells. A hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment
-
K Koeneman F Yeung WK Chung 1999 Osteomimetic properties of prostate cancer cells. A hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment Prostate. 39 246 61
-
(1999)
Prostate.
, vol.39
, pp. 246-61
-
-
Koeneman, K.1
Yeung, F.2
Chung, W.K.3
-
32
-
-
11344267803
-
Prostate cancer bone metastases promote both osteolytic and osteoblastic activity
-
E Keller J Brown 2004 Prostate cancer bone metastases promote both osteolytic and osteoblastic activity J Cell Biochem. 9 718 29
-
(2004)
J Cell Biochem.
, vol.9
, pp. 718-29
-
-
Keller, E.1
Brown, J.2
-
33
-
-
0035987949
-
Bisphosphonates influence the proliferation and the maturation of normal human osteoblasts
-
O Fromigué JJ Body 2002 Bisphosphonates influence the proliferation and the maturation of normal human osteoblasts J Endocrinol Invest. 25 6 539 46
-
(2002)
J Endocrinol Invest.
, vol.25
, Issue.6
, pp. 539-46
-
-
Fromigué, O.1
Body, J.J.2
-
34
-
-
40749088124
-
New research findings on zoledronic acid: Survival, pain, and anti-tumour effects
-
Saad F. New research findings on zoledronic acid: survival, pain, and anti-tumour effects. Cancer Treat Rev. 2007;34(2):183-92.
-
(2007)
Cancer Treat Rev.
, vol.34
, Issue.2
, pp. 183-92
-
-
Saad, F.1
-
35
-
-
9144245854
-
Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy
-
CL Vogel RH Yanagihara AJ Wood FM Schnell C Henderson BH Kaplan 2004 Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy Oncologist. 9 6 687 95
-
(2004)
Oncologist.
, vol.9
, Issue.6
, pp. 687-95
-
-
Vogel, C.L.1
Yanagihara, R.H.2
Wood, A.J.3
Schnell, F.M.4
Henderson, C.5
Kaplan, B.H.6
-
36
-
-
33646869430
-
Effect of zoledronic acid on pain associated with bone metastasis in patients with prostate cancer
-
KP Weinfurt KJ Anstrom LD Castel KA Schulman F Saad 2006 Effect of zoledronic acid on pain associated with bone metastasis in patients with prostate cancer Ann Oncol. 17 6 986 9
-
(2006)
Ann Oncol.
, vol.17
, Issue.6
, pp. 986-9
-
-
Weinfurt, K.P.1
Anstrom, K.J.2
Castel, L.D.3
Schulman, K.A.4
Saad, F.5
|